نتائج البحث

المساهمون: Cristiano G., Nanni J., Sartor C., Parisi S., Marconi G., Barbato F., Arpinati M., Bonifazi F., Curti A., Cavo M., Paolini S., Papayannidis C.

المصدر: Acta Haematologica. 144:688-692

مصطلحات موضوعية: Male, Oncology, medicine.medical_specialty, medicine.medical_treatment, Fusion Proteins, bcr-abl, Protein Kinase Inhibitor, Chromosomal translocation, Hematopoietic stem cell transplantation, Philadelphia chromosome, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, chemistry.chemical_compound, Bone Marrow, Positron Emission Tomography Computed Tomography, hemic and lymphatic diseases, Internal medicine, Medicine, Imidazole, Chemotherapy, Acute leukemia, business.industry, Ponatinib, Myeloid leukemia, Hematology, General Medicine, Middle Aged, medicine.disease, Treatment Outcome, chemistry, Nelarabine, Pyridazine, business, T-cell acute lymphoblastic leukemia, Human, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9817e9a4d94ebcf35ffc08bcc79cc94eTest
https://doi.org/10.1159/000516003Test

8

Effect of nitrogen, phosphorus and zinc fertilization on pecan yield in Argentina

المؤلفون: P. Insausti, E.A. Frusso, F.M. Cavo, R.S. Lavado, P.A. Cipriotti

المصدر: Acta Horticulturae. :215-220

مصطلحات موضوعية: Human fertilization, chemistry, Agronomy, Yield (chemistry), chemistry.chemical_element, Zinc, Horticulture, Nitrogen phosphorus

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::f906c29b8f4cc031984d06000125009aTest
https://doi.org/10.17660/actahortic.2021.1318.31Test

9

INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia

المساهمون: Martinelli, Giovanni, Papayannidis, Cristina, Piciocchi, Alfonso, Robustelli, Valentina, Soverini, Simona, Terragna, Carolina, Marconi, Giovanni, Lemoli, Roberto Massimo, Guolo, Fabio, Fornaro, Antonella, Lunghi, Monia, de Fabritiis, Paolo, Candoni, Anna, Selleri, Carmine, Simonetti, Federico, Bocchia, Monica, Vitale, Antonella, Frison, Luca, Tedeschi, Alessandra, Cuneo, Antonio, Bonifacio, Massimiliano, Martelli, Maria Paola, D'Ardia, Stefano, Trappolini, Silvia, Tosi, Patrizia, Galieni, Piero, Fabbiano, Francesco, Abbenante, Maria Chiara, Granier, Muriel, Zhu, Zhaoyin, Wang, Mingyue, Sartor, Chiara, Paolini, Stefania, Cavo, Michele, Foà, Robin, Fazi, Paola, Vignetti, Marco, Baccarani, Michele

مصطلحات موضوعية: medicine.medical_specialty, Population, Gastroenterology, Disease-Free Survival, chemistry.chemical_compound, Prednisone, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Tyrosine kinase inhibitors, Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), GIMEMA LAL 1811, medicine, Clinical endpoint, Humans, Philadelphia Chromosome, Prospective Studies, education, Adverse effect, Aged, education.field_of_study, biology, business.industry, Ponatinib, Imidazoles, Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Settore MED/15, Rash, Pyridazines, Transplantation, chemistry, Alanine transaminase, biology.protein, medicine.symptom, business, medicine.drug

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532a7ef6c6f327838c21185db5ce9234Test
http://hdl.handle.net/11567/1078678Test

10

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial

المساهمون: Gay F., Musto P., Rota-Scalabrini D., Bertamini L., Belotti A., Galli M., Offidani M., Zamagni E., Ledda A., Grasso M., Ballanti S., Spadano A., Cea M., Patriarca F., D'Agostino M., Capra A., Giuliani N., de Fabritiis P., Aquino S., Palmas A., Gamberi B., Zambello R., Petrucci M.T., Corradini P., Cavo M., Boccadoro M.

مصطلحات موضوعية: Male, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Bortezomib, Combined Modality Therapy, Cyclophosphamide, Dexamethasone, Female, Follow-Up Studies, Hematopoietic Stem Cell Transplantation, Humans, Lenalidomide, Melphalan, Middle Aged, Multiple Myeloma, Oligopeptides, Prognosis, Survival Rate, Thalidomide, Transplantation, Autologous, chemistry.chemical_compound, Maintenance therapy, Monoclonal, Medicine, multiple myeloma, newly diagnosed, carfilzomib, cyclophosphamide, lenalidomide, dexamethasone, induction treatment, autologous stem-cell transplantation, maintenance treatment, phase 2, trial, Multiple myeloma, carfilzomib, trial, induction treatment, Oncology, Oligopeptide, newly diagnosed, Autologous, Human, medicine.drug, medicine.medical_specialty, Prognosi, autologous stem-cell transplantation, Antibodies, Follow-Up Studie, Internal medicine, Autologous transplantation, Transplantation, Antineoplastic Combined Chemotherapy Protocol, maintenance treatment, business.industry, medicine.disease, Settore MED/15, Carfilzomib, chemistry, phase 2, business

وصف الملف: STAMPA

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d4ee9f82acbff156d6f0b7336cbb430aTest
https://hdl.handle.net/2108/318985Test

تنقيح النتائج